Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Tencentson Mar 04, 2024 2:47pm
48 Views
Post# 35913945

RE:RE:RE:COVID and the risk of lung diseases

RE:RE:RE:COVID and the risk of lung diseasesDr kolb sees an interest in lung disease treatment which no doubt his continuing studies will clarify more if it's of interest 
The  point is that Covid 19 as a serious health threat hs greatly reduced - hence lung Infractions sourced by the virus will be much limited in numbers compared to what was seen at pandemic levels
this means probably funds providers will not be attracted to a projet in this area   The winners in Covid solutions are now moved away from it  - at pandemic levels any solution possibility around Covid 19 had great interest - ( no doubt was why czo spoke to it for a period before deciding to stop communicating last year ) 
<< Previous
Bullboard Posts
Next >>